Kenvue (KVUE)

• Market cap: $44.7B
• 1 day: 4.15%
• 5 days: 8.62%
• 1 month: 12.12%
• 3 months: -3.20%
• 6 months: 7.51%
• Year to date: 9.59%
• 1 year: 20.83%
• 5 years: -13.31%
• 10 years: -13.31%
• Sector: Materials
• Industry: Perfumes, Cosmetics & Other Toilet Preparations

About: Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Employees: 22,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

12% more first-time investments, than exits

New positions opened: 116 | Existing positions closed: 104

7% more repeat investments, than reductions

Existing positions increased: 390 | Existing positions reduced: 365

0.12% less ownership

Funds ownership: 99.84% [Q3] → 99.72% (-0.12%) [Q4]

3% less funds holding

Funds holding: 987 [Q3] → 955 (-32) [Q4]

8% less capital invested

Capital invested by funds: $44.2B [Q3] → $40.8B (-$3.34B) [Q4]

17% less call options, than puts

Call options by funds: $166M | Put options by funds: $199M

36% less funds holding in top 10

Funds holding in top 10: 14 [Q3] → 9 (-5) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 10% downside
• Avg. target: $23 1% downside
• High target: $26 11% upside

7 analyst ratings

• positive: 2 29%
• neutral: 5 71%
• negative: 0 0%

Canaccord Genuity Susan Anderson 24% 1-year accuracy 8 / 33 met price target	3% upside $24	Buy Maintained	7 Feb 2025
UBS Peter Grom 32% 1-year accuracy 7 / 22 met price target	10% downside $21	Neutral Maintained	7 Feb 2025
RBC Capital Nik Modi 43% 1-year accuracy 17 / 40 met price target	3% upside $24	Sector Perform Reiterated	3 Feb 2025
Barclays Lauren Lieberman 43% 1-year accuracy 39 / 90 met price target	10% downside $21	Equal-Weight Maintained	17 Jan 2025
Citigroup Filippo Falorni 35% 1-year accuracy 6 / 17 met price target	10% downside $21	Neutral Maintained	15 Jan 2025